Verified peer comparison

ABT vs SYK

Abbott Laboratories compared with Stryker Corporation. This page compares both source-verified company profiles and does not introduce an unverified price target.

ABT

Abbott Laboratories

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

SYK

Stryker Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ABT: Health Care Equipment

SYK: Health Care Equipment

Upside lens

ABT: Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics. Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

SYK: Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment. New implants, neurovascular tools and operating-room technologies can extend share gains.

Risk lens

ABT: Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals. The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized. Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

SYK: Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability. Budget pressure can delay purchases of robots, beds and other capital equipment. Frequent portfolio additions can raise integration, valuation and management-attention risk.